CN110396543A - 一种肿瘤相关基因突变位点筛查方法 - Google Patents

一种肿瘤相关基因突变位点筛查方法 Download PDF

Info

Publication number
CN110396543A
CN110396543A CN201910364296.8A CN201910364296A CN110396543A CN 110396543 A CN110396543 A CN 110396543A CN 201910364296 A CN201910364296 A CN 201910364296A CN 110396543 A CN110396543 A CN 110396543A
Authority
CN
China
Prior art keywords
grna
dna
tumour
sequence
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910364296.8A
Other languages
English (en)
Inventor
陈翀
刘华勇
胡洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Universal Lihua Technology Co Ltd
Original Assignee
Guangzhou Universal Lihua Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Universal Lihua Technology Co Ltd filed Critical Guangzhou Universal Lihua Technology Co Ltd
Priority to CN201910364296.8A priority Critical patent/CN110396543A/zh
Publication of CN110396543A publication Critical patent/CN110396543A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明公开了一种肿瘤相关基因突变位点筛查方法。该技术综合了gRNA靶向识别肿瘤相关突变基因转录产物RNA的优势以及当CRISPR/Cas12a复合物检测到靶标RNA序列时，复合物会切割带有检测标记的报告RNA，释放可检测信号的特点，将CRISPR/Cas12a系统应用在肿瘤相关突变基因检测中，可在室温下对肿瘤相关基因突变位点实现检测高特异性、高灵敏度、高精度的分子检测，还能够实现多位点同时检测，对肿瘤的检测及筛查具有重要的意义。同时该方案检测成本低廉、操作方便快捷，具有非常广阔的应用前景。

Description

一种肿瘤相关基因突变位点筛查方法
技术领域
本发明属于分子检测诊断技术领域。更具体地，涉及一种肿瘤相关基因突变位点筛查方法。
背景技术
肿瘤是当今威胁人类健康的最大疾病，在中国肿瘤已经超过冠心病、脑中风，成为第一位死因。靶向药物针对肿瘤特异性位点，通过在局部维持较高的浓度，提高针对肿瘤的特异性杀伤力，对正常组织细胞作用较小，避免了化疗治疗的副作用。靶向药物与肿瘤基因突变存在关联性，在选用靶向药物治疗之前，需要确认肿瘤的基因突变位点，用来指导、选择靶向药物，以及预知药物是否有效。
目前肿瘤相关基因突变位点的检测技术主要有Sanger测序法、荧光定量PCR法、Fish法、micro array等。传统的基因突变检测方法因技术单次只能检测较少的突变位点、灵敏度低。如Sanger测序法灵敏度低，仅能检测突变率大于20％的高频突变，假阴性率较高，且该技术手段难以胜任多基因多位点的检测，操作繁琐。而聚合酶链反应(PCR)：包括普通PCR、等位基因特异性PCR、实时荧光定量PCR、PCR-基因芯片技术等，主要缺点在于需要依赖PCR仪或昂贵的实时定量PCR仪，及其它多种配套设备，以及专门的PCR实验室和专业操作人员。PCR检测无法实现即时检验、床旁诊断和无特定实验室检测条件的场景应用，因此无法满足基层、用户终端、现场的检验需求。同时，PCR检测可能存在假阳性和灵敏度不足等问题。
另外，CRISPR/Cas是进行基因编辑的强大工具，可以对基因进行定点的精确检测与编辑。在向导RNA(guide RNA，gRNA)和Cas9蛋白的参与下，待编辑的细胞基因组DNA将被看作病毒或外源DNA，被精确剪切。但是，CRISPR/Cas9的应用也有一些限制条件，首先，待编辑的区域附近需要存在相对保守的PAM序列(NGG)，其次向导RNA要与PAM上游的序列碱基互补配对，设计、制备出精确、特异性靶向目标基因的gRNA是CRISPR/Cas12a基因敲除的关键技术，等等。目前尚未有基于CRISPR/Cas12a系统的肿瘤相关突变基因检测方法的相关报道。
发明内容
本发明要解决的技术问题是克服现有肿瘤相关基因突变位点检测技术的缺陷和不足，设计、制备出精确、高效、特异性靶向目标基因的gRNA，这是CRISPR/Cas12a识别靶基因的关键；并基于此构建了一种基于CRISPR/Cas12a系统的肿瘤相关突变基因检测方法及检测试剂盒。
本发明的目的是提供一组基于CRISPR/Cas12a检测肿瘤相关基因突变位点的gRNA组合。
本发明的另一目的是提供一种基于CRISPR/Cas12a的肿瘤相关基因突变位点检测试剂盒。
本发明上述目的通过以下技术方案实现：
本发明提供了一种基于CRISPR/Cas12a的肿瘤相关基因突变位点检测试剂盒，包括Cas12a蛋白和gRNA；所述gRNA以SEQ ID NO.1-35任一或任几个所示靶标位点为靶序列进行设计得到。
所述gRNA的设计原则为：在选取gRNA靶向序列时，靶向序列5’端应具有5’-TTTN-3’序列，且靶向序列本身、靶向序列和其余序列间不形成稳定二级结构。
作为优选的可选择方案，所述gRNA的序列如SEQ ID NO.36-71任一或任几个所示。该gRNA组合也应在本发明的保护范围之内。
另外，上述Cas12a蛋白为具有核酸内切酶活性且具有附属切割活性的Cas12a蛋白。比如LbCas12a、SsCas12a、ScCas12a、FnCas12a、AsCas12a等。
所述ScCas12a的序列如SEQ ID NO.72所示，所述SsCas12a的序列如SEQ ID NO.73所示，所述LbCas12a的序列参照Addgene号pMAL-his-LbCpf1-EC(Plasmid #79008)，FnCas12a的序列参照Addgene号6-His-MBP-TEV-FnCpf1(Plasmid #90094)、AsCas12a的序列参照Addgene号AsCpf1-2NLS(Plasmid#102565)。
另外，优选地，该试剂盒的检测体系包括：不同量的DNA或RPA产物，45nM纯化的LbCas12a，22.5nM gRNA，100nM在LbCas12a切割时可发出荧光的报告DNA链，即非特异单链DNA荧光探针(DNAseAlert QC System,Thermo Scientific)，0.5μl RNase抑制剂(Promega)，及核酸酶检测缓冲液(20mM Tris,60mM NaCl,10mM MgCl 2,pH 7.3)。
检测程序为：在37℃下反应1.5小时，荧光动力检测5分钟一次。
为了实现对多个肿瘤相关基因突变位点的同时检测，便于实现快速多位点初筛的应用场景，我们开发了针对上述肿瘤相关基因突变靶标的多重检测体系，对选择的多种基因突变序列进行分析，以及对应gRNA序列设计分析，根据这些序列的相似性、GC含量、碱基均一性、有无形成二级发夹结构、同一反应有无交叉反应等参数，对反应体系和gRNA组合方式进行优化。本发明的方案可实现对SEQ ID NO.1-35所示35个靶标位点实现多位点同时检测，对于肿瘤的检测筛查具有重要的意义。
本发明具有以下有益效果：
本发明提供了一种用于靶向肿瘤相关突变基因RNA的gRNA组合，本发明还提供了一种基于CRISPR/Cas12a系统的人肿瘤相关突变基因检测方法、检测试剂盒。本发明的检测方法综合了gRNA靶向识别肿瘤相关突变基因转录产物RNA(靶标RNA序列)的优势以及当CRISPR/Cas12a复合物检测到靶标RNA序列时，复合物会切割带有检测标记的报告RNA，释放可检测信号的特点，将CRISPR/Cas12a系统应用在肿瘤相关突变基因检测中，灵敏度高、准确度高，特异性好，可在25-37℃的室温下实现高灵敏、高精度的分子检测，检测限值可达到阿摩尔级(10-18摩尔/L)，实现靶标单分子检测。同时还能实现多位点同时检测，临床检测效果优异，对于肿瘤的检测筛查具有重要的意义。
而且，该方案检测成本低廉、无需大型设备支持、操作方便、快捷、实现床旁检测，便于广泛应用和快速推广，是一种具有巨大商业应用价值的检测方法及检测试剂盒。
附图说明
图1为实施例1中对肿瘤突变位点的不同gRNA检测效果。
图2为实施例2中对肿瘤多基因突变位点gRNA同时检测效果。
具体实施方式
以下结合说明书附图和具体实施例来进一步说明本发明，但实施例并不对本发明做任何形式的限定。本领域技术人员可以理解的是，可以采用本领域常规的替代方法替换本发明实施例中常规的Cas12a基因的克隆、重组表达载体的构建、Cas12a蛋白的表达及纯化、靶核苷酸/目标基因片段的扩增等步骤中的一种或多种，以期获得类似或等同的效果。
除非特别说明，本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。除非特别说明，以下实施例所用试剂和材料均为市购。
实施例1 基于CRISPR/Cas12a系统的肿瘤相关基因突变位点检测
1、CRISPR/Cas12a基因克隆及蛋白表达
采用源自Lachnospiraceae bacterium的Cas12a蛋白基因，经过密码子优化，使基因更适合在哺乳动物细胞中表达。优化后的Cas12a蛋白基因克隆入带6-His组氨酸标签的pET28a质粒，方便蛋白纯化表达。Cas12a蛋白重组表达载体转化，表达菌采用BL21star(DE3)。
将Cas12a蛋白重组表达载体转化后，进行蛋白表达、SDS-PAGE检测以及凝胶柱纯化，获得的纯化后的Cas12a蛋白放-80℃保存。
具体蛋白表达条件为：在培养菌液OD600＝0.6时加入0.5mMIPTG培养4小时。收集菌体进行蛋白纯化。
具体蛋白表达条件为：在培养菌液OD600＝0.6时加入0.5mMIPTG培养4小时。收集菌体进行蛋白纯化。
纯化条件为：将菌体重悬于裂解液(50mM Tris,pH8.0，300mM NaCl，5％甘油，20mM咪唑)，进行超声破碎(70％振幅，2s On/4s Off，3分钟，Sonics 750w超声仪)，离心分离上清液，以镍柱纯化，以含250mM咪唑的裂解液洗脱，浓缩洗脱组分，以Superdex 200，Tricorn10/300凝胶色谱柱进行纯化。SDS-PAGE检测以及凝胶柱纯化，获得的纯化后的Cas12a蛋白，放-80℃保存。
2、靶标序列扩增
靶核苷酸可经过PCR扩增、重组酶聚合酶扩增(RPA)，NASBA等温扩增、或环介导等温扩增(LAMP)、链置换扩增(SDA)、解旋酶依赖性扩增(HDA)和切口酶扩增反应(NEAR)方式扩增靶DNA。
重组酶聚合酶扩增RPA(Recombinase Polymerase Amplification)：
采用NCBI Primer blast设计RPA引物，扩增片段大小为80-120nt，引物的变性温度可为54-67℃、Opt＝60，长度为30-35nt、Opt＝32，引物中GC含量为40-60％，根据设计序列合成DNA引物。
分别参考Basic和BasicRT(TwistDx)试剂盒进行RPA反应，不同的是，在样本核酸加入之前，先加入280mM的MgAc，即乙酸镁。在37℃下反应30分钟。
胶分离以及纯化(采用MinElute gel extraction kit(Qiagen)试剂盒)，纯化后的dsDNA与T7聚合酶37℃孵育过夜(采用T7RNA polymerase(Thermo)试剂盒)，然后用RNeasy mini kit(Qiagen)试剂盒纯化RNA，从而获得靶核RNA。
3、制备gRNA
gRNA引物序列设计原则：选取靶向序列时，靶向序列5’端应具有5’-TTTN-3’序列。且靶向序列本身、靶向序列和其余序列间不形成稳定二级结构，可通过http://www.rgenome.net/cas-designer/在线软件辅助设计。
T7引物序列：TGTAATACGACTCACTATAGGG
gRNA引物结构：
5’-靶向序列-“ATCTACACTTAGTAGAAATTA”-CCCTATAGTGAGTCGTA TTACA-3’
其中“ATCTACACTTAGTAGAAATTA”序列可替换为“ATCTACAACAGTAG AAATTA”或“ATCTACAACAGTAGAAATTA”或“ATCTACAACAGTAGAAATT A”或“GCATGAGAACCATGCATTTC”或“ACCTAATTACTAGGTAATTT”或“ATC TACAAAAGTAGAAATCC”或“ATCTACAATAGTAGAAATTA”或“ATCTACAAA GTAGAAATTAT”或“ATCTACAAACAGTAGAAATT”。
制备gRNA:参照T7RNApolymerase kit(Thermo)试剂盒说明书，将带T7启动子的DNA片段、T7引物、T7聚合酶混合，37℃孵育过夜；再采用RNeasy mini kit(Qiagen)，获得纯化的gRNAs。
T7引物序列：TGTAATACGACTCACTATAGGG
T7gRNA引物序列：
“靶向序列”-5’-ATCTACACTTAGTAGAAATTA-CCCTATAGTGAGTCGTAT TACA-3’
经过大量探索研究，得出了一组基于CRISPR/Cas12a的检测靶标基因及对应的靶向gRNA序列(如表1所示)，还能够实现多位点同时检测。
表1检测靶标基因及对应的靶向gRNA序列
4、基因检测
检测体系包括：不同量的DNA或RPA产物，45nM纯化的LbCas12a，22.5nM gRNA，100nM在LbCas12a切割时可发出荧光的报告DNA链，即非特异单链DNA荧光探针(DNAseAlertQC System,Thermo Scientific)，0.5μl RNase抑制剂(Promega)，及核酸酶检测缓冲液(20mM Tris,60mM NaCl,10mM MgCl 2,pH7.3)。
反应体系置于荧光分析仪(BioTek)，在37℃(除非另有说明)下反应1.5小时，荧光动力检测5分钟一次。
分析反应荧光数据：为了计算去除背景的荧光数据，方便不同条件之间的比较，样品的初始荧光被去除。背景荧光(无靶核苷酸或无gRNA的条件下)会从样品中去除，从而获得扣除背景荧光的数据。
检测结果如图1所示，结果表明：所述Cas12a蛋白和所设计的gRNA可识别切割靶标位点并产生荧光信号。
实施例2 基于CRISPR/Cas12a系统的肿瘤相关多基因突变位点同时检测
为了实现对多个肿瘤相关基因突变位点的同时检测，便于实现快速多位点初筛的应用场景，我们开发了针对上述肿瘤相关基因突变靶标的多重检测体系，对选择的多种基因突变序列进行分析，以及对应gRNA序列设计分析，根据这些序列的相似性、GC含量、碱基均一性、有无形成二级发夹结构、同一反应有无交叉反应等参数，对反应体系和gRNA组合方式进行优化。本发明的方案可实现对SEQ ID NO.1-35所示35个靶标位点实现多位点同时检测。本实施例呈现了肿瘤多基因突变位点检测的一种gRNA组合方案的实验及结果。
1、模板准备
待检测模板选用携带特定突变的阳性标准品，购买自Horizon公司:HD254(EGFRL858R Reference Standard，包含SEQ ID NO.12序列)，HD258(EGFR T790M ReferenceStandard，包含SEQ ID NO.32序列)，HD689(PIK3CA E545K Reference Standard，包含SEQID NO.23序列)，HD290(KRAS G13D Reference Standard，包含SEQ ID NO.34序列)。
2、gRNA制备及突变检测
按照实施例1中步骤3的方法制备好gRNA后，取3种gRNA按等比例混合(SEQ IDNO.47、SEQ ID NO.59、SEQ ID NO.68)，然后按照实施例1中步骤4的方法配制CRISPR/Cas12a检测体系，检测多重gRNA方法检测效果。检测反应中的模板分别为阳性标准品HD254(EGFR L858R，包含SEQ ID NO.12序列)，HD258(EGFR T790M，包含SEQ ID NO.32序列)，HD689(PIK3CA E545K，包含SEQ ID NO.23序列)，HD290(KRAS G13D Reference Standard，包含SEQ ID NO.34序列)。实验中无靶核酸的样本为阴性对照，阳性标准品HD254单独加对应gRNA(SEQ ID NO.47)为阳性对照，HD689为非特异性对照，其它条件不变。配置好体系后置于荧光分析仪(BioTek)，在37℃(除非另有说明)下反应1.5小时，荧光动力检测5分钟一次。
3、检测结果如图2所示。实验结果表明，特异性的靶标基因标准品(分别包含SEQID NO.12，SEQ ID NO.32，SEQ ID NO.23序列)加入3重gRNA反应体系后，均有荧光产生，结果为阳性；非特异性的标准品(包含SEQ ID NO.34序列)加入多重gRNA反应体系后，结果为阴性。说明实验建立的基于CRISPR/Cas12a系统的肿瘤相关多基因突变位点同时检测有良好的检测效果与特异性。
本领域技术人员可以理解的是，可以采用本领域常规的替代方法替换本发明实施例中常规的Cas12a基因的克隆、重组表达载体的构建、Cas12a蛋白的表达及纯化、靶核苷酸/目标基因片段的扩增等步骤中的一种或多种，以期获得类似或等同的效果。
另外，上文中SEQ ID NO.72和SEQ ID NO.73所示序列如下：
SEQ ID NO.72：(ScCas12a的序列)
ATGCAGACCCTGTTTGAGAACTTCACAAATCAGTACCCAGTGTCCAAGACCCTGCGCTTTGAGCTGATCCCCCAGGGCAAGACAAAGGACTTCATCGAGCAGAAGGGCCTGCTGAAGAAGGATGAGGACCGGGCCGAGAAGTATAAGAAGGTGAAGAACATCATCGATGAGTACCACAAGGACTTCATCGAGAAGTCTCTGAATGGCCTGAAGCTGGACGGCCTGGAGGAATACAAGACCCTGTATCTGAAGCAGGAGAAGGACGATAAGGATAAGAAGGCCTTTGACAAGGAGAAGGAGAACCTGCGCAAGCAGATCGCCAATGCCTTCCGGAACAATGAGAAGTTTAAGACACTGTTCGCCAAGGAGCTGATCAAGAACGATCTGATGTCTTTCGCCTGCGAGGAGGACAAGAAGAATGTGAAGGAGTTTGAGGCCTTCACCACATACTTCACCGGCTTCCACCAGAACCGCGCCAATATGTACGTGGCCGATGAGAAGAGAACAGCCATCGCCAGCAGGCTGATCCACGAGAACCTGCCAAAGTTTATCGACAATATCAAGATCTTCGAGAAGATGAAGAAGGAGGCCCCCGAGCTGCTGTCTCCTTTCAACCAGACCCTGAAGGATATGAAGGACGTGATCAAGGGCACCACACTGGAGGAGATCTTTAGCCTGGATTATTTCAACAAGACCCTGACACAGAGCGGCATCGACATCTACAATTCCGTGATCGGCGGCAGAACCCCTGAGGAGGGCAAGACAAAGATCAAGGGCCTGAACGAGTACATCAATACCGACTTCAACCAGAAGCAGACAGACAAGAAGAAGCGGCAGCCAAAGTTCAAGCAGCTGTATAAGCAGATCCTGAGCGATAGGCAGAGCCTGTCCTTTATCGCCGAGGCCTTCAAGAACGACACCGAGATCCTGGAGGCCATCGAGAAGTTTTACGTGAATGAGCTGCTGCACTTCAGCAATGAGGGCAAGTCCACAAACGTGCTGGACGCCATCAAGAATGCCGTGTCTAACCTGGAGAGCTTTAACCTGACCAAGATCTATTTCCGCTCCGGCACCTCTCTGACAGACGTGAGCCGGAAGGTGTTTGGCGAGTGGAGCATCATCAATAGAGCCCTGGACAACTACTATGCCACCACATATCCAATCAAGCCCAGAGAGAAGTCTGAGAAGTACGAGGAGAGGAAGGAGAAGTGGCTGAAGCAGGACTTCAACGTGAGCCTGATCCAGACCGCCATCGATGAGTACGACAACGAGACAGTGAAGGGCAAGAACAGCGGCAAAGTGATCGTCGATTATTTTGCCAAGTTCTGCGACGATAAGGAGACAGACCTGATCCAGAAGGTGAACGAGGGCTACATCGCCGTGAAGGATCTGCTGAATACACCCTGTCCTGAGAACGAGAAGCTGGGCAGCAATAAGGACCAGGTGAAGCAGATCAAGGCCTTTATGGATTCTATCATGGACATCATGCACTTCGTGCGCCCCCTGAGCCTGAAGGATACCGACAAGGAGAAGGATGAGACATTCTACTCCCTGTTCACACCTCTGTACGACCACCTGACCCAGACAATCGCCCTGTATAACAAGGTGCGGAACTATCTGACCCAGAAGCCTTACAGCACAGAGAAGATCAAGCTGAACTTCGAGAACAGCACCCTGCTGGGCGGCTGGGATCTGAATAAGGAGACAGACAACACAGCCATCATCCTGAGGAAGGAAAACCTGTACTATCTGGGCATCATGGACAAGAGGCACAATCGCATCTTTCGGAACGTGCCCAAGGCCGATAAGAAGGACTCTTGCTACGAGAAGATGGTGTATAAGCTGCTGCCTGGCGCCAACAAGATGCTGCCAAAGGTGTTCTTTTCTCAGAGCAGAATCCAGGAGTTTACCCCTTCCGCCAAGCTGCTGGAGAACTACGAAAATGAGACACACAAGAAGGGCGATAATTTCAACCTGAATCACTGTCACCAGCTGATCGATTTCTTTAAGGACTCTATCAACAAGCACGAGGATTGGAAGAATTTCGACTTTAGGTTCAGCGCCACCTCCACCTACGCCGACCTGAGCGGCTTTTACCACGAGGTGGAGCACCAGGGCTACAAGATCTCTTTTCAGAGCATCGCCGATTCCTTCATCGACGATCTGGTGAACGAGGGCAAGCTGTACCTGTTCCAGATCTATAATAAGGACTTTTCCCCATTCTCTAAGGGCAAGCCCAACCTGCACACCCTGTACTGGAAGATGCTGTTTGATGAGAACAATCTGAAGGACGTGGTGTATAAGCTGAATGGCGAGGCCGAGGTGTTCTACCGCAAGAAGAGCATTGCCGAGAAGAACACCACAATCCACAAGGCCAATGAGTCCATCATCAACAAGAATCCTGATAACCCAAAGGCCACCAGCACCTTCAACTATGATATCGTGAAGGACAAGAGATACACCATCGACAAGTTTCAGTTCCACATCCCAATCACAATGAACTTTAAGGCCGAGGGCATCTTCAACATGAATCAGAGGGTGAATCAGTTCCTGAAGGCCAATCCCGATATCAACATCATCGGCATCGACAGAGGCGAGAGGCACCTGCTGTACTATGCCCTGATCAACCAGAAGGGCAAGATCCTGAAGCAGGATACCCTGAATGTGATCGCCAACGAGAAGCAGAAGGTGGACTACCACAATCTGCTGGATAAGAAGGAGGGCGACCGCGCAACCGCAAGGCAGGAGTGGGGCGTGATCGAGACAATCAAGGAGCTGAAGGAGGGCTATCTGTCCCAGGTCATCCACAAGCTGACCGATCTGATGATCGAGAACAATGCCATCATCGTGATGGAGGACCTGAACTTTGGCTTCAAGCGGGGCAGACAGAAGGTGGAGAAGCAGGTGTATCAGAAGTTTGAGAAGATGCTGATCGATAAGCTGAATTACCTGGTGGACAAGAATAAGAAGGCAAACGAGCTGGGAGGCCTGCTGAACGCATTCCAGCTGGCCAATAAGTTTGAGTCCTTCCAGAAGATGGGCAAGCAGAACGGCTTTATCTTCTACGTGCCCGCCTGGAATACCTCTAAGACAGATCCTGCCACCGGCTTTATCGACTTCCTGAAGCCCCGCTATGAGAACCTGAATCAGGCCAAGGATTTCTTTGAGAAGTTTGACTCTATCCGGCTGAACAGCAAGGCCGATTACTTTGAGTTCGCCTTTGACTTCAAGAATTTCACCGAGAAGGCCGATGGCGGCAGAACCAAGTGGACAGTGTGCACCACAAACGAGGACAGATATGCCTGGAATAGGGCCCTGAACAATAACAGGGGCAGCCAGGAGAAGTACGACATCACAGCCGAGCTGAAGTCCCTGTTCGATGGCAAGGTGGACTATAAGTCTGGCAAGGATCTGAAGCAGCAGATCGCCAGCCAGGAGTCCGCCGACTTCTTTAAGGCCCTGATGAAGAACCTGTCCATCACCCTGTCTCTGAGACACAATAACGGCGAGAAGGGCGATAATGAGCAGGACTACATCCTGTCCCCTGTGGCCGATTCTAAGGGCCGCTTCTTTGACTCCCGGAAGGCCGACGATGACATGCCAAAGAATGCCGACGCCAACGGCGCCTATCACATCGCCCTGAAGGGCCTGTGGTGTCTGGAGCAGATCAGCAAGACCGATGACCTGAAGAAGGTGAAGCTGGCCATCTCCAACAAGGAGTGGCTGGAGTTCGTGCAGACACTGAAGGGCAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGATGTTCCAGATTACGCTTATCCCTACGACGTGCCTGATTATGCATACCCATATGATGTCCCCGACTATGCC
SEQ ID NO.73：(SsCas12a的序列)
ATGCAGACCCTGTTTGAGAACTTCACAAATCAGTACCCAGTGTCCAAGACCCTGCGCTTTGAGCTGATCCCCCAGGGCAAGACAAAGGACTTCATCGAGCAGAAGGGCCTGCTGAAGAAGGATGAGGACCGGGCCGAGAAGTATAAGAAGGTGAAGAACATCATCGATGAGTACCACAAGGACTTCATCGAGAAGTCTCTGAATGGCCTGAAGCTGGACGGCCTGGAGAAGTACAAGACCCTGTATCTGAAGCAGGAGAAGGACGATAAGGATAAGAAGGCCTTTGACAAGGAGAAGGAGAACCTGCGCAAGCAGATCGCCAATGCCTTCCGGAACAATGAGAAGTTTAAGACACTGTTCGCCAAGGAGCTGATCAAGAACGATCTGATGTCTTTCGCCTGCGAGGAGGACAAGAAGAATGTGAAGGAGTTTGAGGCCTTCACCACATACTTCACCGGCTTCCACCAGAACCGCGCCAATATGTACGTGGCCGATGAGAAGAGAACAGCCATCGCCAGCAGGCTGATCCACGAGAACCTGCCAAAGTTTATCGACAATATCAAGATCTTCGAGAAGATGAAGAAGGAGGCCCCCGAGCTGCTGTCTCCTTTCAACCAGACCCTGAAGGATATGAAGGACGTGATCAAGGGCACCACACTGGAGGAGATCTTTAGCCTGGATTATTTCAACAAGACCCTGACACAGAGCGGCATCGACATCTACAATTCCGTGATCGGCGGCAGAACCCCTGAGGAGGGCAAGACAAAGATCAAGGGCCTGAACGAGTACATCAATACCGACTTCAACCAGAAGCAGACAGACAAGAAGAAGCGGCAGCCAAAGTTCAAGCAGCTGTATAAGCAGATCCTGAGCGATAGGCAGAGCCTGTCCTTTATCGCCGAGGCCTTCAAGAACGACACCGAGATCCTGGAGGCCATCGAGAAGTTTTACGTGAATGAGCTGCTGCACTTCAGCAATGAGGGCAAGTCCACAAACGTGCTGGACGCCATCAAGAATGCCGTGTCTAACCTGGAGAGCTTTAACCTGACCAAGATGTATTTCCGCTCCGGCGCCTCTCTGACAGACGTGAGCCGGAAGGTGTTTGGCGAGTGGAGCATCATCAATAGAGCCCTGGACAACTACTATGCCACCACATATCCAATCAAGCCCAGAGAGAAGTCTGAGAAGTACGAGGAGAGGAAGGAGAAGTGGCTGAAGCAGGACTTCAACGTGAGCCTGATCCAGACCGCCATCGATGAGTACGACAACGAGACAGTGAAGGGCAAGAACAGCGGCAAAGTGATCGCCGATTATTTTGCCAAGTTCTGCGACGATAAGGAGACAGACCTGATCCAGAAGGTGAACGAGGGCTACATCGCCGTGAAGGATCTGCTGAATACACCCTGTCCTGAGAACGAGAAGCTGGGCAGCAATAAGGACCAGGTGAAGCAGATCAAGGCCTTTATGGATTCTATCATGGACATCATGCACTTCGTGCGCCCCCTGAGCCTGAAGGATACCGACAAGGAGAAGGATGAGACATTCTACTCCCTGTTCACACCTCTGTACGACCACCTGACCCAGACAATCGCCCTGTATAACAAGGTGCGGAACTATCTGACCCAGAAGCCTTACAGCACAGAGAAGATCAAGCTGAACTTCGAGAACAGCACCCTGCTGGGCGGCTGGGATCTGAATAAGGAGACAGACAACACAGCCATCATCCTGAGGAAGGATAACCTGTACTATCTGGGCATCATGGACAAGAGGCACAATCGCATCTTTCGGAACGTGCCCAAGGCCGATAAGAAGGACTTCTGCTACGAGAAGATGGTGTATAAGCTGCTGCCTGGCGCCAACAAGATGCTGCCAAAGGTGTTCTTTTCTCAGAGCAGAATCCAGGAGTTTACCCCTTCCGCCAAGCTGCTGGAGAACTACGCCAATGAGACACACAAGAAGGGCGATAATTTCAACCTGAATCACTGTCACAAGCTGATCGATTTCTTTAAGGACTCTATCAACAAGCACGAGGATTGGAAGAATTTCGACTTTAGGTTCAGCGCCACCTCCACCTACGCCGACCTGAGCGGCTTTTACCACGAGGTGGAGCACCAGGGCTACAAGATCTCTTTTCAGAGCGTGGCCGATTCCTTCATCGACGATCTGGTGAACGAGGGCAAGCTGTACCTGTTCCAGATCTATAATAAGGACTTTTCCCCATTCTCTAAGGGCAAGCCCAACCTGCACACCCTGTACTGGAAGATGCTGTTTGATGAGAACAATCTGAAGGACGTGGTGTATAAGCTGAATGGCGAGGCCGAGGTGTTCTACCGCAAGAAGAGCATTGCCGAGAAGAACACCACAATCCACAAGGCCAATGAGTCCATCATCAACAAGAATCCTGATAACCCAAAGGCCACCAGCACCTTCAACTATGATATCGTGAAGGACAAGAGATACACCATCGACAAGTTTCAGTTCCACATCCCAATCACAATGAACTTTAAGGCCGAGGGCATCTTCAACATGAATCAGAGGGTGAATCAGTTCCTGAAGGCCAATCCCGATATCAACATCATCGGCATCGACAGAGGCGAGAGGCACCTGCTGTACTATGCCCTGATCAACCAGAAGGGCAAGATCCTGAAGCAGGATACCCTGAATGTGATCGCCAACGAGAAGCAGAAGGTGGACTACCACAATCTGCTGGATAAGAAGGAGGGCGACCGCGCAACCGCAAGGCAGGAGTGGGGCGTGATCGAGACAATCAAGGAGCTGAAGGAGGGCTATCTGTCCCAGGTCATCCACAAGCTGACCGATCTGATGATCGAGAACAATGCCATCATCGTGATGGAGGACCTGAACTTTGGCTTCAAGCGGGGCAGACAGAAGGTGGAGAAGCAGGTGTATCAGAAGTTTGAGAAGATGCTGATCGATAAGCTGAATTACCTGGTGGACAAGAATAAGAAGGCAAACGAGCTGGGAGGCCTGCTGAACGCATTCCAGCTGGCCAATAAGTTTGAGTCCTTCCAGAAGATGGGCAAGCAGAACGGCTTTATCTTCTACGTGCCCGCCTGGAATACCTCTAAGACAGATCCTGCCACCGGCTTTATCGACTTCCTGAAGCCCCGCTATGAGAACCTGAATCAGGCCAAGGATTTCTTTGAGAAGTTTGACTCTATCCGGCTGAACAGCAAGGCCGATTACTTTGAGTTCGCCTTTGACTTCAAGAATTTCACCGAGAAGGCCGATGGCGGCAGAACCAAGTGGACAGTGTGCACCACAAACGAGGACAGATATGCCTGGAATAGGGCCCTGAACAATAACAGGGGCAGCCAGGAGAAGTACGACATCACAGCCGAGCTGAAGTCCCTGTTCGATGGCAAGGTGGACTATAAGTCTGGCAAGGATCTGAAGCAGCAGATCGCCAGCCAGGAGTCCGCCGACTTCTTTAAGGCCCTGATGAAGAACCTGTCCATCACCCTGTCTCTGAGACACAATAACGGCGAGAAGGGCGATAATGAGCAGGACTACATCCTGTCCCCTGTGGCCGATTCTAAGGGCCGCTTCTTTGACTCCCGGAAGGCCGACGATGACATGCCAAAGAATGCCGACGCCAACGGCGCCTATCACATCGCCCTGAAGGGCCTGTGGTGTCTGGAGCAGATCAGCAAGACCGATGACCTGAAGAAGGTGAAGCTGGCCATCTCCAACAAGGAGTGGCTGGAGTTCGTGCAGACACTGAAGGGCAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGATGTTCCAGATTACGCTTATCCCTACGACGTGCCTGATTATGCATACCCATATGATGTCCCCGACTATGCC
SEQUENCE LISTING
<110> 广州普世利华科技有限公司
<120> 一种肿瘤相关基因突变位点筛查方法
<130>
<160> 73
<170> PatentIn version 3.3
<210> 1
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 1
gaggcagtct ttactcacct gtagatgtct cgggccatcc cgaagtctcc aatcttggcc 60
a 61
<210> 2
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 2
taactaatta ggtttcttgt tttattttag cgaagaatag ccagaattca gcaaatcgaa 60
a 61
<210> 3
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 3
cgagcagatg taaatagtaa aaagacgttg cgagaagttg gaagtgtgaa agcattgatg 60
g 61
<210> 4
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 4
gctaataccc tgcaaatagc agaaataaaa gaaaagattg gaactaggtc agctgaagat 60
c 61
<210> 5
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 5
ggagcgaaat ctccctccaa aagtggtgct cagacaccca aaagtccacc tgaacactat 60
g 61
<210> 6
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 6
ccaccacctc ctcaaacagc tcaaaccaag cgagaagtac ctaaaaataa agcacctact 60
g 61
<210> 7
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 7
aactgatggg acccactcca tcgagatttc actgtagcta gaccaaaatc acctattttt 60
a 61
<210> 8
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 8
tcaaactgat gggacccact ccatcgagat ttcactgtag ctagaccaaa atcacctatt 60
t 61
<210> 9
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 9
catttaccac agttgataca catttcttca tcaatcatag ccacaacttg ctctacgttg 60
c 61
<210> 10
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 10
tctcttgttt tagatgttaa atcacactta cgttgtctgg aaagtcagcc tttagttcag 60
t 61
<210> 11
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 11
aagttaaaat tcccgtcgct atcaaggaat taagagaagc aacatctccg aaagccaaca 60
a 61
<210> 12
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 12
cgcagcatgt caagatcaca gattttgggc tggccaaact gctgggtgcg gaagagaaag 60
a 61
<210> 13
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 13
tcaagatcac agattttggg ctggccaaac tgctgggtgc ggaagagaaa gaataccatg 60
c 61
<210> 14
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 14
tagacaacta cctttctacg gacgtgggat cctgcaccct cgtctgcccc ctgcacaacc 60
a 61
<210> 15
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 15
agaaacccat gtatgaagta cagtggaagg ttgttgagga gataaatgga aacaattatg 60
t 61
<210> 16
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 16
acaaagattt gtgattttgg tctagccaga gacatcaaga atgattctaa ttatgtggtt 60
a 61
<210> 17
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 17
atttcagtgt tacttacctg tcttgtcttt gctgatgttt caataaaagg aattccataa 60
c 61
<210> 18
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 18
tttcagtgtt acttacctgt cttgtctttg ctgatgtttc aataaaagga attccataac 60
t 61
<210> 19
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 19
ggcttgtaag tgcccgaagt gtaagcccaa ctacagaaat ggtttcaaat gaatctgtag 60
a 61
<210> 20
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 20
cttgccagag acatgtatga taaagaatac tatagtgtac acaacaaaac aggtgcaaag 60
c 61
<210> 21
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 21
agctggattg tcagtgcgct tttcccaaca ccacctgctc caaccaccac cagtttgtac 60
t 61
<210> 22
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 22
tgaagatctg tgactttggc ctggccagag acatcatgca tgattcgaac tatgtgtcga 60
a 61
<210> 23
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 23
tctacacgag atcctctctc tgaaatcact gagcaggaga aagattttct atggagtcac 60
a 61
<210> 24
<211> 51
<212> DNA
<213> 肿瘤靶基因
<400> 24
atttgacatg atttgggata gaggaccatt agttgccatc aatccaggtg a 51
<210> 25
<211> 51
<212> DNA
<213> 肿瘤靶基因
<400> 25
taaatgtatg attttatgca ggtttccaga ccggggacac agtgtagttg g 51
<210> 26
<211> 51
<212> DNA
<213> 肿瘤靶基因
<400> 26
attgactgtc tttttgaaaa gttatatcta cttacagaaa agtaaatgag a 51
<210> 27
<211> 52
<212> DNA
<213> 肿瘤靶基因
<400> 27
ggtttttgcc atatatatat atatataagt aggagagggc gaacctctgg ca 52
<210> 28
<211> 51
<212> DNA
<213> 肿瘤靶基因
<400> 28
tttagtagag atggggtttc actacattgg ccaggctggt ctcaaactcc t 51
<210> 29
<211> 51
<212> DNA
<213> 肿瘤靶基因
<400> 29
ctttaaagag ctcttttgtc tttcattatc tcttccctgt ttggaccaca t 51
<210> 30
<211> 51
<212> DNA
<213> 肿瘤靶基因
<400> 30
ctaagaaacc aaattttagg aacttcttag tgctctccac aaaggggtct t 51
<210> 31
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 31
aactgatggg acccactcca tcgagatttc actgtagcta gaccaaaatc acctattttt 60
a 61
<210> 32
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 32
tctgcctcac ctccaccgtg cagctcatca cgcagctcat gcccttcggc tgcctcctgg 60
a 61
<210> 33
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 33
cagctcatca cgcagctcat gcccttcggc tgcctcctgg actatgtccg ggaacacaaa 60
g 61
<210> 34
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 34
agctgtatcg tcaaggcact cttgcctacg ccaccagctc caactaccac aagtttatat 60
t 61
<210> 35
<211> 61
<212> DNA
<213> 肿瘤靶基因
<400> 35
tgtatcgtca aggcactctt gcctacgcca ccagctccaa ctaccacaag tttatattca 60
g 61
<210> 36
<211> 21
<212> DNA
<213> gRNA的序列
<400> 36
ctcacctgta gatgtctcgg g 21
<210> 37
<211> 21
<212> DNA
<213> gRNA的序列
<400> 37
gcgaagaata gccagaattc a 21
<210> 38
<211> 21
<212> DNA
<213> gRNA的序列
<400> 38
acacttccaa cttctcgcaa c 21
<210> 39
<211> 21
<212> DNA
<213> gRNA的序列
<400> 39
cttttatttc tgctatttgc a 21
<210> 40
<211> 21
<212> DNA
<213> gRNA的序列
<400> 40
ggtgtctgag caccactttt g 21
<210> 41
<211> 21
<212> DNA
<213> gRNA的序列
<400> 41
ggtacttctc gcttggtttg a 21
<210> 42
<211> 21
<212> DNA
<213> gRNA的序列
<400> 42
actgtagcta gaccaaaatc a 21
<210> 43
<211> 21
<212> DNA
<213> gRNA的序列
<400> 43
gtctagctac agtgaaatct c 21
<210> 44
<211> 21
<212> DNA
<213> gRNA的序列
<400> 44
ttcatcaatc atagccacaa c 21
<210> 45
<211> 21
<212> DNA
<213> gRNA的序列
<400> 45
cagacaacgt aagtgtgatt t 21
<210> 46
<211> 21
<212> DNA
<213> gRNA的序列
<400> 46
ggagatgttg cttctcttaa t 21
<210> 47
<211> 21
<212> DNA
<213> gRNA的序列
<400> 47
gccagcccaa aatctgtgat c 21
<210> 48
<211> 21
<212> DNA
<213> gRNA的序列
<400> 48
ggctggccaa actgctgggt g 21
<210> 49
<211> 21
<212> DNA
<213> gRNA的序列
<400> 49
tacggacgtg ggatcctgca c 21
<210> 50
<211> 21
<212> DNA
<213> gRNA的序列
<400> 50
tctcctcaac aaccttccac t 21
<210> 51
<211> 21
<212> DNA
<213> gRNA的序列
<400> 51
catttatctc ctcaacaacc t 21
<210> 52
<211> 21
<212> DNA
<213> gRNA的序列
<400> 52
gtctagccag agacatcaag a 21
<210> 53
<211> 21
<212> DNA
<213> gRNA的序列
<400> 53
ttgaaacatc agcaaagaca a 21
<210> 54
<211> 21
<212> DNA
<213> gRNA的序列
<400> 54
ctgatgtttc aataaaagga a 21
<210> 55
<211> 21
<212> DNA
<213> gRNA的序列
<400> 55
tgtagttggg cttacacttc g 21
<210> 56
<211> 21
<212> DNA
<213> gRNA的序列
<400> 56
ttgtgtacac tatagtattc t 21
<210> 57
<211> 21
<212> DNA
<213> gRNA的序列
<400> 57
ccaacaccac ctgctccaac c 21
<210> 58
<211> 21
<212> DNA
<213> gRNA的序列
<400> 58
gcctggccag agacatcatg c 21
<210> 59
<211> 21
<212> DNA
<213> gRNA的序列
<400> 59
tcctgctcag tgatttcaga g 21
<210> 60
<211> 21
<212> DNA
<213> gRNA的序列
<400> 60
ggatagagga ccattagttg c 21
<210> 61
<211> 21
<212> DNA
<213> gRNA的序列
<400> 61
tgcaggtttc cagaccgggg a 21
<210> 62
<211> 21
<212> DNA
<213> gRNA的序列
<400> 62
aaaagttata tctacttaca g 21
<210> 63
<211> 22
<212> DNA
<213> gRNA的序列
<400> 63
ccatatatat atatatataa gt 22
<210> 64
<211> 21
<212> DNA
<213> gRNA的序列
<400> 64
actacattgg ccaggctggt c 21
<210> 65
<211> 21
<212> DNA
<213> gRNA的序列
<400> 65
tctttcatta tctcttccct g 21
<210> 66
<211> 21
<212> DNA
<213> gRNA的序列
<400> 66
ggaacttctt agtgctctcc a 21
<210> 67
<211> 21
<212> DNA
<213> gRNA的序列
<400> 67
actgtagcta gaccaaaatc a 21
<210> 68
<211> 21
<212> DNA
<213> gRNA的序列
<400> 68
acgcagctca tgcccttcgg c 21
<210> 69
<211> 21
<212> DNA
<213> gRNA的序列
<400> 69
cttcggctgc ctcctggact a 21
<210> 70
<211> 22
<212> DNA
<213> gRNA的序列
<400> 70
tgcctacgcc accagctcca ac 22
<210> 71
<211> 24
<212> DNA
<213> gRNA的序列
<400> 71
tacgccacca gctccaacta ccac 24
<210> 72
<211> 3885
<212> DNA
<213> ScCas12a的序列
<400> 72
atgcagaccc tgtttgagaa cttcacaaat cagtacccag tgtccaagac cctgcgcttt 60
gagctgatcc cccagggcaa gacaaaggac ttcatcgagc agaagggcct gctgaagaag 120
gatgaggacc gggccgagaa gtataagaag gtgaagaaca tcatcgatga gtaccacaag 180
gacttcatcg agaagtctct gaatggcctg aagctggacg gcctggagga atacaagacc 240
ctgtatctga agcaggagaa ggacgataag gataagaagg cctttgacaa ggagaaggag 300
aacctgcgca agcagatcgc caatgccttc cggaacaatg agaagtttaa gacactgttc 360
gccaaggagc tgatcaagaa cgatctgatg tctttcgcct gcgaggagga caagaagaat 420
gtgaaggagt ttgaggcctt caccacatac ttcaccggct tccaccagaa ccgcgccaat 480
atgtacgtgg ccgatgagaa gagaacagcc atcgccagca ggctgatcca cgagaacctg 540
ccaaagttta tcgacaatat caagatcttc gagaagatga agaaggaggc ccccgagctg 600
ctgtctcctt tcaaccagac cctgaaggat atgaaggacg tgatcaaggg caccacactg 660
gaggagatct ttagcctgga ttatttcaac aagaccctga cacagagcgg catcgacatc 720
tacaattccg tgatcggcgg cagaacccct gaggagggca agacaaagat caagggcctg 780
aacgagtaca tcaataccga cttcaaccag aagcagacag acaagaagaa gcggcagcca 840
aagttcaagc agctgtataa gcagatcctg agcgataggc agagcctgtc ctttatcgcc 900
gaggccttca agaacgacac cgagatcctg gaggccatcg agaagtttta cgtgaatgag 960
ctgctgcact tcagcaatga gggcaagtcc acaaacgtgc tggacgccat caagaatgcc 1020
gtgtctaacc tggagagctt taacctgacc aagatctatt tccgctccgg cacctctctg 1080
acagacgtga gccggaaggt gtttggcgag tggagcatca tcaatagagc cctggacaac 1140
tactatgcca ccacatatcc aatcaagccc agagagaagt ctgagaagta cgaggagagg 1200
aaggagaagt ggctgaagca ggacttcaac gtgagcctga tccagaccgc catcgatgag 1260
tacgacaacg agacagtgaa gggcaagaac agcggcaaag tgatcgtcga ttattttgcc 1320
aagttctgcg acgataagga gacagacctg atccagaagg tgaacgaggg ctacatcgcc 1380
gtgaaggatc tgctgaatac accctgtcct gagaacgaga agctgggcag caataaggac 1440
caggtgaagc agatcaaggc ctttatggat tctatcatgg acatcatgca cttcgtgcgc 1500
cccctgagcc tgaaggatac cgacaaggag aaggatgaga cattctactc cctgttcaca 1560
cctctgtacg accacctgac ccagacaatc gccctgtata acaaggtgcg gaactatctg 1620
acccagaagc cttacagcac agagaagatc aagctgaact tcgagaacag caccctgctg 1680
ggcggctggg atctgaataa ggagacagac aacacagcca tcatcctgag gaaggaaaac 1740
ctgtactatc tgggcatcat ggacaagagg cacaatcgca tctttcggaa cgtgcccaag 1800
gccgataaga aggactcttg ctacgagaag atggtgtata agctgctgcc tggcgccaac 1860
aagatgctgc caaaggtgtt cttttctcag agcagaatcc aggagtttac cccttccgcc 1920
aagctgctgg agaactacga aaatgagaca cacaagaagg gcgataattt caacctgaat 1980
cactgtcacc agctgatcga tttctttaag gactctatca acaagcacga ggattggaag 2040
aatttcgact ttaggttcag cgccacctcc acctacgccg acctgagcgg cttttaccac 2100
gaggtggagc accagggcta caagatctct tttcagagca tcgccgattc cttcatcgac 2160
gatctggtga acgagggcaa gctgtacctg ttccagatct ataataagga cttttcccca 2220
ttctctaagg gcaagcccaa cctgcacacc ctgtactgga agatgctgtt tgatgagaac 2280
aatctgaagg acgtggtgta taagctgaat ggcgaggccg aggtgttcta ccgcaagaag 2340
agcattgccg agaagaacac cacaatccac aaggccaatg agtccatcat caacaagaat 2400
cctgataacc caaaggccac cagcaccttc aactatgata tcgtgaagga caagagatac 2460
accatcgaca agtttcagtt ccacatccca atcacaatga actttaaggc cgagggcatc 2520
ttcaacatga atcagagggt gaatcagttc ctgaaggcca atcccgatat caacatcatc 2580
ggcatcgaca gaggcgagag gcacctgctg tactatgccc tgatcaacca gaagggcaag 2640
atcctgaagc aggataccct gaatgtgatc gccaacgaga agcagaaggt ggactaccac 2700
aatctgctgg ataagaagga gggcgaccgc gcaaccgcaa ggcaggagtg gggcgtgatc 2760
gagacaatca aggagctgaa ggagggctat ctgtcccagg tcatccacaa gctgaccgat 2820
ctgatgatcg agaacaatgc catcatcgtg atggaggacc tgaactttgg cttcaagcgg 2880
ggcagacaga aggtggagaa gcaggtgtat cagaagtttg agaagatgct gatcgataag 2940
ctgaattacc tggtggacaa gaataagaag gcaaacgagc tgggaggcct gctgaacgca 3000
ttccagctgg ccaataagtt tgagtccttc cagaagatgg gcaagcagaa cggctttatc 3060
ttctacgtgc ccgcctggaa tacctctaag acagatcctg ccaccggctt tatcgacttc 3120
ctgaagcccc gctatgagaa cctgaatcag gccaaggatt tctttgagaa gtttgactct 3180
atccggctga acagcaaggc cgattacttt gagttcgcct ttgacttcaa gaatttcacc 3240
gagaaggccg atggcggcag aaccaagtgg acagtgtgca ccacaaacga ggacagatat 3300
gcctggaata gggccctgaa caataacagg ggcagccagg agaagtacga catcacagcc 3360
gagctgaagt ccctgttcga tggcaaggtg gactataagt ctggcaagga tctgaagcag 3420
cagatcgcca gccaggagtc cgccgacttc tttaaggccc tgatgaagaa cctgtccatc 3480
accctgtctc tgagacacaa taacggcgag aagggcgata atgagcagga ctacatcctg 3540
tcccctgtgg ccgattctaa gggccgcttc tttgactccc ggaaggccga cgatgacatg 3600
ccaaagaatg ccgacgccaa cggcgcctat cacatcgccc tgaagggcct gtggtgtctg 3660
gagcagatca gcaagaccga tgacctgaag aaggtgaagc tggccatctc caacaaggag 3720
tggctggagt tcgtgcagac actgaagggc aaaaggccgg cggccacgaa aaaggccggc 3780
caggcaaaaa agaaaaaggg atcctaccca tacgatgttc cagattacgc ttatccctac 3840
gacgtgcctg attatgcata cccatatgat gtccccgact atgcc 3885
<210> 73
<211> 3885
<212> DNA
<213> SsCas12a的序列
<400> 73
atgcagaccc tgtttgagaa cttcacaaat cagtacccag tgtccaagac cctgcgcttt 60
gagctgatcc cccagggcaa gacaaaggac ttcatcgagc agaagggcct gctgaagaag 120
gatgaggacc gggccgagaa gtataagaag gtgaagaaca tcatcgatga gtaccacaag 180
gacttcatcg agaagtctct gaatggcctg aagctggacg gcctggagaa gtacaagacc 240
ctgtatctga agcaggagaa ggacgataag gataagaagg cctttgacaa ggagaaggag 300
aacctgcgca agcagatcgc caatgccttc cggaacaatg agaagtttaa gacactgttc 360
gccaaggagc tgatcaagaa cgatctgatg tctttcgcct gcgaggagga caagaagaat 420
gtgaaggagt ttgaggcctt caccacatac ttcaccggct tccaccagaa ccgcgccaat 480
atgtacgtgg ccgatgagaa gagaacagcc atcgccagca ggctgatcca cgagaacctg 540
ccaaagttta tcgacaatat caagatcttc gagaagatga agaaggaggc ccccgagctg 600
ctgtctcctt tcaaccagac cctgaaggat atgaaggacg tgatcaaggg caccacactg 660
gaggagatct ttagcctgga ttatttcaac aagaccctga cacagagcgg catcgacatc 720
tacaattccg tgatcggcgg cagaacccct gaggagggca agacaaagat caagggcctg 780
aacgagtaca tcaataccga cttcaaccag aagcagacag acaagaagaa gcggcagcca 840
aagttcaagc agctgtataa gcagatcctg agcgataggc agagcctgtc ctttatcgcc 900
gaggccttca agaacgacac cgagatcctg gaggccatcg agaagtttta cgtgaatgag 960
ctgctgcact tcagcaatga gggcaagtcc acaaacgtgc tggacgccat caagaatgcc 1020
gtgtctaacc tggagagctt taacctgacc aagatgtatt tccgctccgg cgcctctctg 1080
acagacgtga gccggaaggt gtttggcgag tggagcatca tcaatagagc cctggacaac 1140
tactatgcca ccacatatcc aatcaagccc agagagaagt ctgagaagta cgaggagagg 1200
aaggagaagt ggctgaagca ggacttcaac gtgagcctga tccagaccgc catcgatgag 1260
tacgacaacg agacagtgaa gggcaagaac agcggcaaag tgatcgccga ttattttgcc 1320
aagttctgcg acgataagga gacagacctg atccagaagg tgaacgaggg ctacatcgcc 1380
gtgaaggatc tgctgaatac accctgtcct gagaacgaga agctgggcag caataaggac 1440
caggtgaagc agatcaaggc ctttatggat tctatcatgg acatcatgca cttcgtgcgc 1500
cccctgagcc tgaaggatac cgacaaggag aaggatgaga cattctactc cctgttcaca 1560
cctctgtacg accacctgac ccagacaatc gccctgtata acaaggtgcg gaactatctg 1620
acccagaagc cttacagcac agagaagatc aagctgaact tcgagaacag caccctgctg 1680
ggcggctggg atctgaataa ggagacagac aacacagcca tcatcctgag gaaggataac 1740
ctgtactatc tgggcatcat ggacaagagg cacaatcgca tctttcggaa cgtgcccaag 1800
gccgataaga aggacttctg ctacgagaag atggtgtata agctgctgcc tggcgccaac 1860
aagatgctgc caaaggtgtt cttttctcag agcagaatcc aggagtttac cccttccgcc 1920
aagctgctgg agaactacgc caatgagaca cacaagaagg gcgataattt caacctgaat 1980
cactgtcaca agctgatcga tttctttaag gactctatca acaagcacga ggattggaag 2040
aatttcgact ttaggttcag cgccacctcc acctacgccg acctgagcgg cttttaccac 2100
gaggtggagc accagggcta caagatctct tttcagagcg tggccgattc cttcatcgac 2160
gatctggtga acgagggcaa gctgtacctg ttccagatct ataataagga cttttcccca 2220
ttctctaagg gcaagcccaa cctgcacacc ctgtactgga agatgctgtt tgatgagaac 2280
aatctgaagg acgtggtgta taagctgaat ggcgaggccg aggtgttcta ccgcaagaag 2340
agcattgccg agaagaacac cacaatccac aaggccaatg agtccatcat caacaagaat 2400
cctgataacc caaaggccac cagcaccttc aactatgata tcgtgaagga caagagatac 2460
accatcgaca agtttcagtt ccacatccca atcacaatga actttaaggc cgagggcatc 2520
ttcaacatga atcagagggt gaatcagttc ctgaaggcca atcccgatat caacatcatc 2580
ggcatcgaca gaggcgagag gcacctgctg tactatgccc tgatcaacca gaagggcaag 2640
atcctgaagc aggataccct gaatgtgatc gccaacgaga agcagaaggt ggactaccac 2700
aatctgctgg ataagaagga gggcgaccgc gcaaccgcaa ggcaggagtg gggcgtgatc 2760
gagacaatca aggagctgaa ggagggctat ctgtcccagg tcatccacaa gctgaccgat 2820
ctgatgatcg agaacaatgc catcatcgtg atggaggacc tgaactttgg cttcaagcgg 2880
ggcagacaga aggtggagaa gcaggtgtat cagaagtttg agaagatgct gatcgataag 2940
ctgaattacc tggtggacaa gaataagaag gcaaacgagc tgggaggcct gctgaacgca 3000
ttccagctgg ccaataagtt tgagtccttc cagaagatgg gcaagcagaa cggctttatc 3060
ttctacgtgc ccgcctggaa tacctctaag acagatcctg ccaccggctt tatcgacttc 3120
ctgaagcccc gctatgagaa cctgaatcag gccaaggatt tctttgagaa gtttgactct 3180
atccggctga acagcaaggc cgattacttt gagttcgcct ttgacttcaa gaatttcacc 3240
gagaaggccg atggcggcag aaccaagtgg acagtgtgca ccacaaacga ggacagatat 3300
gcctggaata gggccctgaa caataacagg ggcagccagg agaagtacga catcacagcc 3360
gagctgaagt ccctgttcga tggcaaggtg gactataagt ctggcaagga tctgaagcag 3420
cagatcgcca gccaggagtc cgccgacttc tttaaggccc tgatgaagaa cctgtccatc 3480
accctgtctc tgagacacaa taacggcgag aagggcgata atgagcagga ctacatcctg 3540
tcccctgtgg ccgattctaa gggccgcttc tttgactccc ggaaggccga cgatgacatg 3600
ccaaagaatg ccgacgccaa cggcgcctat cacatcgccc tgaagggcct gtggtgtctg 3660
gagcagatca gcaagaccga tgacctgaag aaggtgaagc tggccatctc caacaaggag 3720
tggctggagt tcgtgcagac actgaagggc aaaaggccgg cggccacgaa aaaggccggc 3780
caggcaaaaa agaaaaaggg atcctaccca tacgatgttc cagattacgc ttatccctac 3840
gacgtgcctg attatgcata cccatatgat gtccccgact atgcc 3885

Claims (6)

1.一组基于CRISPR/Cas12a检测肿瘤相关基因突变位点的gRNA组合，其特征在于，所述gRNA组合包括SEQ ID NO.36-71任一或任几个所示gRNA。
2.一种基于CRISPR/Cas12a的肿瘤相关基因突变位点检测试剂盒，其特征在于，包括Cas12a蛋白和gRNA，所述gRNA为SEQ ID NO.36-71任一或任几个所示的gRNA。
3.根据权利要求2所述检测试剂盒，其特征在于，所述Cas12a蛋白为LbCas12a、SsCas12a、ScCas12a、FnCas12a或AsCas12a。
4.根据权利要求2所述检测试剂盒，其特征在于，还包括非特异单链DNA荧光探针、RNase抑制剂和核酸酶检测缓冲液。
5.根据权利要求2所述检测试剂盒，其特征在于，检测体系包括：不同量的DNA或RPA产物，45nM Cas12a，22.5nM gRNA，100nM在Cas12a切割时可发出荧光的报告DNA链，0.5μlRNase抑制剂，及核酸酶检测缓冲液。
6.根据权利要求2所述检测试剂盒，其特征在于，检测程序为：在37℃下反应1.5小时，荧光动力检测5分钟一次。
CN201910364296.8A 2019-04-30 2019-04-30 一种肿瘤相关基因突变位点筛查方法 Pending CN110396543A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910364296.8A CN110396543A (zh) 2019-04-30 2019-04-30 一种肿瘤相关基因突变位点筛查方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910364296.8A CN110396543A (zh) 2019-04-30 2019-04-30 一种肿瘤相关基因突变位点筛查方法

Publications (1)

Publication Number Publication Date
CN110396543A true CN110396543A (zh) 2019-11-01

Family

ID=68322916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910364296.8A Pending CN110396543A (zh) 2019-04-30 2019-04-30 一种肿瘤相关基因突变位点筛查方法

Country Status (1)

Country Link
CN (1) CN110396543A (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111893166A (zh) * 2020-07-31 2020-11-06 浙江科途医学科技有限公司 用于ccdc6-ret融合基因检测的试剂组合物、试剂盒及检测系统
CN111909987A (zh) * 2020-07-31 2020-11-10 浙江科途医学科技有限公司 用于kif5b-ret融合基因检测的试剂组合物、试剂盒及检测系统
CN113373223A (zh) * 2021-06-01 2021-09-10 武汉大学 FLT3-D835Y突变检测的CRISPR-Cas系统及其应用
CN113913499A (zh) * 2020-12-25 2022-01-11 山东舜丰生物科技有限公司 利用Cas12j效应蛋白检测目标突变的方法
CN113913498A (zh) * 2020-12-14 2022-01-11 山东舜丰生物科技有限公司 一种基于crispr技术检测目标突变的方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552904A (zh) * 2010-12-23 2012-07-11 徐州医学院附属医院 人类免疫缺陷病毒膜分子gp120功能域与人TGF-β1的重组分子
CN108513582A (zh) * 2015-06-18 2018-09-07 布罗德研究所有限公司 新型crispr酶以及系统
US20180273935A1 (en) * 2015-06-05 2018-09-27 The Regents Of The University Of California Methods and compositions for generating crispr/cas guide rnas
EP3391907A1 (en) * 2017-04-20 2018-10-24 iOmx Therapeutics AG Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
CN109295054A (zh) * 2017-07-25 2019-02-01 广州普世利华科技有限公司 用于靶向病原体基因RNA的gRNA及基于C2c2的病原体基因的检测方法、检测试剂盒
CN109295055A (zh) * 2017-07-25 2019-02-01 广州普世利华科技有限公司 基于C2c2的肿瘤相关突变基因的gRNA、检测方法、检测试剂盒
CN109402115A (zh) * 2018-09-06 2019-03-01 广州普世利华科技有限公司 靶向Rett突变基因RNA的gRNA及的Rett突变基因的检测方法、检测试剂盒
CN109666662A (zh) * 2018-12-12 2019-04-23 广州普世利华科技有限公司 新型ScCas12a在核酸检测方面的应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552904A (zh) * 2010-12-23 2012-07-11 徐州医学院附属医院 人类免疫缺陷病毒膜分子gp120功能域与人TGF-β1的重组分子
US20180273935A1 (en) * 2015-06-05 2018-09-27 The Regents Of The University Of California Methods and compositions for generating crispr/cas guide rnas
CN108513582A (zh) * 2015-06-18 2018-09-07 布罗德研究所有限公司 新型crispr酶以及系统
EP3391907A1 (en) * 2017-04-20 2018-10-24 iOmx Therapeutics AG Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
CN109295054A (zh) * 2017-07-25 2019-02-01 广州普世利华科技有限公司 用于靶向病原体基因RNA的gRNA及基于C2c2的病原体基因的检测方法、检测试剂盒
CN109295055A (zh) * 2017-07-25 2019-02-01 广州普世利华科技有限公司 基于C2c2的肿瘤相关突变基因的gRNA、检测方法、检测试剂盒
CN109402115A (zh) * 2018-09-06 2019-03-01 广州普世利华科技有限公司 靶向Rett突变基因RNA的gRNA及的Rett突变基因的检测方法、检测试剂盒
CN109666662A (zh) * 2018-12-12 2019-04-23 广州普世利华科技有限公司 新型ScCas12a在核酸检测方面的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JONATHAN S等: ""Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6"", 《SCIENCE》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111893166A (zh) * 2020-07-31 2020-11-06 浙江科途医学科技有限公司 用于ccdc6-ret融合基因检测的试剂组合物、试剂盒及检测系统
CN111909987A (zh) * 2020-07-31 2020-11-10 浙江科途医学科技有限公司 用于kif5b-ret融合基因检测的试剂组合物、试剂盒及检测系统
CN111893166B (zh) * 2020-07-31 2021-11-26 北京科途医学科技有限公司 用于ccdc6-ret融合基因检测的试剂组合物、试剂盒及检测系统
CN113913498A (zh) * 2020-12-14 2022-01-11 山东舜丰生物科技有限公司 一种基于crispr技术检测目标突变的方法
CN113913499A (zh) * 2020-12-25 2022-01-11 山东舜丰生物科技有限公司 利用Cas12j效应蛋白检测目标突变的方法
CN113373223A (zh) * 2021-06-01 2021-09-10 武汉大学 FLT3-D835Y突变检测的CRISPR-Cas系统及其应用

Similar Documents

Publication Publication Date Title
US11795501B2 (en) Methods for next generation genome walking and related compositions and kits
CN100422339C (zh) 短串联重复基因座的多重扩增
US11015213B2 (en) Method of preparing cell free nucleic acid molecules by in situ amplification
WO2018165459A1 (en) Method for highly sensitive dna methylation analysis
CN110396543A (zh) 一种肿瘤相关基因突变位点筛查方法
AU2016250529A1 (en) Method to increase sensitivity of next generation sequencing
CN110396557B (zh) 一种基于CRISPR/Cas12a的特异性HPV核酸检测方法
CN107603971B (zh) 一种原位杂交探针的制备方法
Park et al. Comparison of RNA-based next-generation sequencing assays for the detection of NTRK gene fusions
CN109680044B (zh) 一种基于选择性消除野生链背景干扰的基因突变检测方法
US20220275450A1 (en) Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence
US20180187267A1 (en) Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence
CN109486919B (zh) 一种pcr扩增试剂及其应用
KR101990953B1 (ko) 암 유발 유전자 이상을 분석하는 방법
CN116445621A (zh) 同时检测肺癌和结直肠癌的dna和rna流程引物组和试剂盒
WO2023148235A1 (en) Methods of enriching nucleic acids
US20220025437A1 (en) NOVEL METHOD OF COMBINED MOLECULAR CLAMPING AND ALLELE SPECIFIC qPCR TECHNOLOGY FOR KRAS G12C MUTATION DETECTION
CN110195102A (zh) 一种β地中海贫血基因分型方法
CN108517364A (zh) 基于56个y染色体snp遗传标记的法医学复合检测试剂盒
CN106636442A (zh) 一种人类肿瘤基因变异联合检测试剂盒
CN110396540B (zh) 一种血友病基因突变位点的检测方法
CN107385097B (zh) 检测smad4基因v354l位点突变的试剂盒
Yin et al. PCR-based procedures to isolate insertion sites of DNA elements
KR20190038464A (ko) Ras/braf 돌연변이 검출용 조성물 및 이를 포함하는 키트
CN106636333A (zh) Pdgfra基因突变检测试剂盒

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination